Celemics, Inc.

News & Events

View the various news of Celemics

Celemics signs an agreement to supply BTSeq™ to Sangon Biotech Co., Ltd., a Chinese genetic analysis company

  • Post category:NEWS

Celemics signs an agreement to supply BTSeq™ to Sangon Biotech Co., Ltd., a Chinese genetic analysis company

– Successive global expansion following the signing of a supply contract with Tsingke in July
– Wide range of business expectations, such as expansion of high value-added applications and replacement of Sanger sequencing

October 28, 2021, Seoul, Korea: Celemics, Inc. (CEO Young-hoon Lee, Hyo-ki Kim / www.celemics.com), an NGS-based sequencing solution and
bioinformatics tech company, announced on the 28th that it has signed an annual supply agreement of BTSeq™ (Barcode-Tagged Sequencing)
with Sangon Biotech Co., Ltd., located in Shanghai, China.

Sangon, which successfully signed a supply agreement this time, operates 12 subsidiaries throughout China, including in Nanjing and Qingdao,
with the main focus on its headquarters in Shanghai. With annual sales of 164 billion KRW ($ 140.3 million) in 2020, it is considered one of
the most important Sanger Sequencing companies along with Tsingke and BGI. After signing the first global BTSeq™ supply agreement with
Tsingke in July, Celemics signed the second global supply agreement in three months, securing two top Chinese genetic analysis companies as customers,
and solidified its position in China’s NGS market.

In this annual supply agreement, the minimum supply quantity is 100,000 reactions (rxn), and provides both Celemics’s BTSeq™ kits and bioinformatics software
to various service fields operated by Sangon. It was arranged in a short period as it was determined that the technical skills and commercial value of BTSeq™ were
in line with the future strategic direction of Sangon to expand with a high value-added business such as NGS. A company official explained thatas BTSeq™ can be applied to
various application fields, it can also be used to not only develop high value-added NGS application developments, but also replace Sanger sequencing in the existing flagship businesses.

Sangon CEO Wang Gye-song (王啓松) said, “After we set the business direction by expanding high value-added applications, we expect that our new strategy will gain momentum
through BTSeq™’s wide scalability.”

Young-hoon Lee, co-CEO of Celemics, said, “Even when the schedule was delayed due to the coronavirus pandemic, the fact that the contract with Tsingke was executed through
extensive verification procedures serves as a good reference and is receiving a lot of attention from customers. While promoting BTSeq™’s overseas expansion, we have prioritized
the Chinese NGS market, which has the highest global growth potential. I’m glad we had great results. We will do our best to secure our position in other Asian, and Middle Eastern,
and European countries as well.”